Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2016
Richter's Transformation in the Era of Kinase Inhibitor Therapy: A ReviewEmily C Ayers, Anthony R Mato
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemiaBruce D Cheson, Anthony R Mato
Hematology. American Society of Hematology. Education Program|December 4, 2020
Approaches for relapsed CLL after chemotherapy-free frontline regimensLindsey E Roeker, Anthony R Mato
Bone Marrow Transplantation|April 25, 2006
Autologous stem cell transplant in ALL: who should we be transplanting in first remission?A R Mato, S M Luger
The Oncologist|May 9, 2012
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideAnthony R Mato, Tatyana Feldman, André Goy
Current Opinion in Hematology|February 28, 2008
Novel strategies for relapsed and refractory acute myeloid leukemiaAnthony R Mato, Alicia Morgans, Selina M Luger
Drugs|December 21, 2021
Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of ChemoimmunotherapyLindsey E Roeker, Meghan Thompson, Anthony R Mato
Microbial Drug Resistance (Larchmont, N.Y.)|October 1, 1996
Multiplicity of genetic backgrounds among vancomycin-resistant Enterococcus faecium isolates recovered from an outbreak in a New York City hospitalR Mato, H de Lencastre, R B Roberts, et al.
Pageof 12